1 May 2019 in Clinical Lymphoma Myeloma and Leukemia
1 May 2019 in Clinical Lymphoma Myeloma and Leukemia
1 October 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Purpose/Objective(s) Local-regional therapy in BC is largely guided by clinico-pathologic features, whereas molecular biology and intrinsic gene signatures of the cancer are used to prescribe risk-tailored systemic therapy. The objective of this study was to evaluate the incidence of local-regional relapse in early stage BC. Further, to evaluate the correlation of Oncotype Dx score, in addition to the clinico-pathologic features with risk of relapse. Materials/Methods This was an institutional review board approved retrospective study from our institutional database. We identified 1355 patients with ER+ Stage I and II BC who had undergone Oncotype Dx testing. For this study, we included only those patients with unilateral BC and minimum follow-up of 2 years (n = 792). Patients were treated with mastectomy, or lumpectomy and radiation (RT) + systemic therapy at the discretion of treating physician. We scored patients based on the first site of failure: local-regional relapse (LRR) only, distant metastases (DM) only, and both (LRR+DM). The association between clinical covariates (Age: ≥50, 2 cm; Grade), Oncotype Dx score (<18, ≥18), local treatment (mastectomy vs. lumpectomy/RT), and failure events was evaluated by univariable and multivariable Cox proportional hazards models. Survival was estimated using the Kaplan-Meier and log-rank test method. Results Tabled 1 Abstract 116; Table 1 Factors Influencing LRR and DM on multivariate analysis Risk Factors Local-regional relapse Hazard Ratio Distant Metastasis Hazard Ratio T-size >2 cm 2.77 (95% CI = 1.07-7.15; P = 0.034)* 6.7 (95% CI 2.8-16.3; P<0.0001)* Oncotype Score ≥18 2.8 (95% CI = 1.08-7.36; P = 0.03)* 5.2 (95% CI 1.7-15.5; P = 0.003)* Open table in a new tab Conclusion Our study suggests that in addition to clinicopathologic variables Oncotype Dx score may provide useful information regarding risk of LRR. Further research is needed to establish a role for molecular and gene profiles in providing risk-tailored delivery of radiation. Acknowledgment Grant support by Ellen Blair Research Fund.